ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Cmv-Specific Cell-Mediated Immune Reconstitution in High-Risk Hematopoietic Cell Transplant Recipients Receiving Letermovir Prophylaxis

M. Z. Abidi1, K. Garth1, J. Gutman2, A. Weinberg1

1Medicine, Infectious Disease, University of Colorado, Aurora, CO, 2Medicine, Hematology and Oncology, University of Colorado, Aurora, CO

Meeting: 2022 American Transplant Congress

Abstract number: 53

Keywords: Cytomeglovirus, Prophylaxis, T cells

Topic: Clinical Science » Infection Disease » 24 - All Infections (Excluding Kidney & Viral Hepatitis)

Session Information

Session Name: Cytomegalovirus and other Herpes Viruses

Session Type: Rapid Fire Oral Abstract

Date: Sunday, June 5, 2022

Session Time: 3:30pm-5:00pm

 Presentation Time: 4:00pm-4:10pm

Location: Hynes Ballroom B

*Purpose: In the absence of antiviral prophylaxis following Hematopoietic Cell Transplant (HCT), the incidence of clinically significant cytomegalovirus reactivation (cCMV) is 30% in CMV seropositive HCT recipients (CMV R+). At our institution, letermovir prophylaxis through approximately Day 100 is used in CMV R+ high-risk (HR) (cord blood, haplocord) HCT recipients. We hypothesized that clinically nonsignificant CMV reactivation (nCMV) during letermovir prophylaxis may lead to the reconstitution of CMV specific cell-mediated immunity (CMV-IR), which may protect the host against CMV disease after letermovir discontinuation.

*Methods: Blood samples from CMV R+ HR on letermovir were tested by dual color CMV specific IL2/IFNg FLUOROSpot pre-transplant and on Days 100, 182 and 360 post-HCT. Clinical and virologic information were obtained from medical records. cCMV was defined by CMV DNA ≥5000 IU /ml of whole blood.

*Results: Among 64 participants enrolled to date, 43 were eligible for this interim analysis, which included participants with CMV FLUOROSpot results ≥20 IFNg spot-forming cells/106 PBMC at any study timepoint pre- or post-HCT and/or CMV reactivation and follow up ≥100 days post-HCT. The median age was 49 years (range 23-75), 23 were women, 28 were white non-Hispanic, 12 Hispanic, 3 Asian, 1 Black. The most common underlying malignancy was acute myeloid leukemia (n=22), followed by acute lymphocytic leukemia (n=14). 27 participants had early CMV-IR at Day 100 albeit only 17 had detectable CMV DNAemia during prophylaxis. Among participants with early CMV-IR, 4 developed CMV disease at Day >100, 1 cCMV, and 12 nCMV. Acute graft versus host disease (aGVHD) preceded all episodes of CMV disease and cCMV, and 4 nCMV episodes.

Five of the 16 participants with late (Day >100) or no CMV-IR had CMV reactivation during prophylaxis, including 2 participants who developed CMV disease, 3 cCMV, and 13 nCMV. The episodes of CMV disease and cCMV and 5 nCMV were preceded by aGVHD. Interestingly, 4 participants with CMV reactivation while on letermovir prophylaxis, including 2 with CMV disease, did not have early CMV-IR.

*Conclusions: Most CMV R+ HR HCT recipients developed early CMV-IR while on letermovir prophylaxis, presumably in response to CMV reactivation. However, CMV reactivation during letermovir prophylaxis was not always accompanied by viremia and not all documented episodes of CMV reactivation were accompanied by early CMV-IR. aGVHD was an important contributor to symptomatic or asymptomatic cCMV.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Abidi MZ, Garth K, Gutman J, Weinberg A. Cmv-Specific Cell-Mediated Immune Reconstitution in High-Risk Hematopoietic Cell Transplant Recipients Receiving Letermovir Prophylaxis [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/cmv-specific-cell-mediated-immune-reconstitution-in-high-risk-hematopoietic-cell-transplant-recipients-receiving-letermovir-prophylaxis/. Accessed May 30, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences